Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABT-089 in Attention Deficit-Hyperactivity Disorder (ADHD)
NCT00640185Phase 2Completed
- Sponsor
- AbbVie Inc.
- Start
- Mar 2008
- Primary completion
- Aug 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pozanicline in attention deficit hyperactivity disorder (ADHD) (3 arms), sponsored by AbbVie Inc. Primary endpoint: Conners' Adult ADHD Rating Scale Investigator Rated Total Score at Day 56. Started Mar 2008; status: completed.
02
Drugs
pozanicline
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00640185.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00640185.